CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. SLDB today announced that Joel Schneider, PhD., Chief Technology Officer, will participate in a webcast question and answer session at the upcoming Chardan Annual Genetic Medicines Conference at 8:30 a.m. ET on October 8th in New York, NY.
A live audio webcast of the Chardan presentation will be available on the Events page of the Investors section of the Company website. A replay of the Chardan presentation will also be archived for approximately 30 days on the Events & Presentations page.
About Solid Biosciences
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. For more information, please visit www.solidbio.com.
Investor Contact:
Carlo Tanzi, Ph.D.
Kendall Investor Relations
617-337-4680
investors@solidbio.com
Media Contact:
Lindsay Deefholts
ScientPR
416-301-7966
media@solidbio.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.